- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04639180
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
April 23, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
687
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Linna Wang, MD
- Phone Number: 021-60453196
- Email: linna.wang@hengrui.com
Study Contact Backup
- Name: Jing Wu, MD
- Phone Number: 010-67166319
- Email: jing.wu@hengrui.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China
- The First Affiliated Hospital of Chongqing Medical University
-
-
Guangzhou
-
Nanjin, Guangzhou, China
- Guangxi Medical University Affiliated Tumor Hospital
-
-
Guizhou
-
Guiyang, Guizhou, China
- Guizhou Cancer Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai, Shanghai, China
- Zhongshan Hospital, Fudan University
-
-
Tianjin
-
Tianjin, Tianjin, China
- Tianjin Medical University Cancer Institute and Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects with a histopathological diagnosis of HCC
- Subjects who have undergone a curative resection or ablation (radiofrequency ablation [RFA] or microwave ablation [MVA] only)
- No previous systematic treatment and locoregional therapy for HCC prior to randomization
- Absence of major macrovascular invasion
- No extrahepatic spread
- Full recovery from Curative resection or ablation within 4 weeks prior to randomization
- High risk for HCC recurrence after resection or ablation
- For patients who received post-operative transarterial chemoembolization: full recovery from the procedure within 4 weeks prior to randomization
- Child-Pugh Class: Grade A
- ECOG-PS score: 0 or 1
- Subjects with HCV- RNA (+) must receive antiviral therapy
- Adequate organ function
Exclusion Criteria:
- Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar HCC; other active malignant tumor except HCC within 5 years or simultaneously
- Evidence of residual lesion, recurrence, and metastasis at randomization;
- Moderate-to-severe ascites with clinical symptoms
- History of hepatic encephalopathy
- History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal haemorrhage
- Active or history of autoimmune disease
- Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity
- Cardiac clinical symptom or cardiovascular disease that is not well controlled
- Severe infection within 4 weeks prior to the start of study treatment
- HIV infection
- Known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug
- Subjects with inadequately controlled hypertension or history of hypertensive crisis or hypertensive encephalopathy
- Thrombosis or thromboembolic event within 6 months prior to the start of study treatment
- Known genetic or acquired hemorrhage or thrombotic tendency
- Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
- Serious non-healing or dehiscing wound
- Major Curative procedure within four weeks
- Factors to affect oral administration
- Previous or current presence of metastasis to central nervous system
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))
Drug: Camrelizumab; Drug: Rivoceranib (Apatinib)
|
Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
|
No Intervention: Control group (Active surveillance)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC)
Time Frame: Randomization up to approximately 43 months
|
RFS is defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC as determined by BIRC, or death from any cause (whichever occurs first).
|
Randomization up to approximately 43 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RFS Rate at 24 and 36 Months, as Assessed by the Investigator
Time Frame: Randomization up to 24 months and up to 36 months
|
Randomization up to 24 months and up to 36 months
|
|
Time to Recurrence (TTR) as determined by the investigator and by BIRC
Time Frame: Randomization up to approximately 43 months
|
TTR defined as the time from randomization to first documented occurrence of local, regional, or metastatic HCC
|
Randomization up to approximately 43 months
|
Overall Survival (OS)
Time Frame: Randomization up to approximately 43 months
|
OS is defined as the time from randomization to death from any cause
|
Randomization up to approximately 43 months
|
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
Time Frame: Baseline up to approximately 43 months
|
Baseline up to approximately 43 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2021
Primary Completion (Anticipated)
July 31, 2024
Study Completion (Anticipated)
July 31, 2024
Study Registration Dates
First Submitted
November 19, 2020
First Submitted That Met QC Criteria
November 19, 2020
First Posted (Actual)
November 20, 2020
Study Record Updates
Last Update Posted (Actual)
April 25, 2023
Last Update Submitted That Met QC Criteria
April 23, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Recurrence
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- SHR-1210-III-325
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma (HCC)
-
BayerNot yet recruitingHepatocellular Carcinoma (HCC)United States
-
Chugai PharmaceuticalRecruitingHepatocellular Carcinoma (HCC)Taiwan, Japan
-
Bristol-Myers SquibbCompletedHepatocellular Carcinoma (HCC)France, Korea, Republic of, Taiwan, United States, Singapore, Philippines, Malaysia, Hong Kong
-
Institut für Klinische Krebsforschung IKF GmbH...Active, not recruitingHepatocellular Carcinoma (HCC)Germany
-
Boston Scientific CorporationBiocompatabilities UK LtdWithdrawnHepatocellular Carcinoma (HCC)
-
University Hospital, BordeauxCompleted
-
Shanghai Zhongshan HospitalWest China Hospital; Tongji Hospital; Anhui Provincial HospitalUnknownHepatocellular Carcinoma (HCC)China
-
Medical College of WisconsinNorthwestern University; GuerbetCompletedHepatocellular Carcinoma (HCC)United States
-
University Hospital, MontpellierCompleted
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)China, Singapore
Clinical Trials on Camrelizumab
-
Shandong Provincial HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Peking UniversityNot yet recruiting
-
Hebei Medical University Fourth HospitalRecruiting
-
Nanfang Hospital of Southern Medical UniversityRecruitingNasopharyngeal Carcinoma | Oligometastasis | RadiotherapyChina
-
Zhejiang Cancer HospitalNot yet recruitingUterine Cervical Neoplasms | Oncolytic Virotherapy | CamrelizumabChina
-
Fudan UniversityRecruiting
-
Fujian Medical University Union HospitalRecruitingRadiotherapy | Immunotherapy | Esophageal NeoplasmChina
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Henan Provincial People's HospitalNot yet recruiting